SMARCA4 and ovarian cancer: We analyzed the genome-wide CRISPR/Cas9 knockout screens from the Cancer Dependency Map (DepMap, https://depmap.org) across 37 ovarian cancer cell lines (Supplementary Data 1): five are SMARCA4/2-deficient, including three SCCOHT cell lines (BIN-67, SCCOHT-1, COV434)13,36 and two dedifferentiated ovarian cancer cell lines (TOV-112D, OVK18)29,36, while the remaining 32 are SMARCA4/2-proficient29,37.